Dr Courtney DiNardo (The University of Texas MD Anderson Cancer Center, Houston, United States) joins touchONCOLOGY to discuss the key findings from the VIALE-A study and the safety and efficacy of venetoclax plus azacitadine in patients with acute myeloid leukaemia and (NCT02203773 and NCT02287233.)
1. What are the limitations of current therapeutic options for patients with acute myeloid leukaemia who cannot receive or tolerate intensive chemotherapy or a bone marrow transplant? (0:04)
2. Could you tell us about the VIALE-A study and its major findings? (1:02)
3. What were the safety findings of this study, and what, if any, was the incidence of tumour lysis syndrome? (4:20)
4. Which patients are most likely to benefit from this treatment regimen and in which patients is it contraindicated? (6:28)
Abstract LB2601, A Randomized, Double-Blind, Placebo-Controlled Study Of Venetoclax With Azacitidine vs Azacitidine In Treatment-Naïve Patients With Acute Myeloid Leukemia Ineligible for Intensive Therapy-VIALE-A, was presented as a late-breaking abstract at EHA25 Virtual and is available here.
Speaker disclosure: The VIALE-A study was supported by Abbvie.
Support: Interview and filming supported by Touch Medical Media in collaboration with Earned Media.
Filmed at the Virtual Edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), June 2020.
Related Videos In Leukaemia
Courtney DiNardo, EHA 2020: Venetoclax plus Azacitadine in AML and the VIALE-A Study
Dr Courtney DiNardo (The University of Texas MD Anderson Cancer Center, Houston, United States) joins touchONCOLOGY to discuss the key findings from the VIALE-A study and the safety and efficacy of venetoclax plus azacitadine in patients with acute myeloid leukaemia and (NCT02203773 and NCT02287233.) Questions 1. What are the limitations of current therapeutic options for […]
Mikkael Sekeres, ASCO20: New combination therapy in patients with MDS/CMML or LB AML
It was a pleasure to speak to Mikkael Sekeres to discuss the presentation of the phase II study of pevonedistat + azacitidine versus azacitidine in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia (Clinicaltrials.gov identifier: NCT02610777). Questions 1. What are the limitations of hypomethylating agents such as, 5-azacitidine in the treatment […]
Othman Al Sawaf, ASCO20: Results of the Phase III CLL14 Trial for Chronic Lymphocytic Leukaemia
We were delighted to speak to Othman Al-Sawaf to discuss the data presented at ASCO20 Virtual Scientific Programme on the phase III CLL14 trial, which found that the BCL2 inhibitor venetoclax plus the monoclonal antibody obinutuzumab prolonged progression-free survival vs obinutuzumab and chlorambucil in patients with previously untreated chronic lymphocytic leukemia and coexisting conditions. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!